Table 2 HPV association in oropharyngeal tumours with clinicopathological characteristics.

From: Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial

Variable

HPV-negative

HPV-positive

p-value

N (%)

N (%)

63 (82.9)

13 (17.1)

Age (years ± SD)

57.08 (7.11)

58.46 (6.40)

0.562*1

Sex

Man

55 (84.6)

10 (15.4)

0.388*2

Woman

8 (72.7)

3 (27.3)

 

TNM

III

5 (71.4)

2 (28.6)

0.166*3

IVA

45 (80.4)

11 (19.6)

 

IVB

13 (100.0)

0 (0.0)

 

Grade

Well differentiated

10 (83.3)

2 (16.7)

0.016*3

Moderately differentiated

36 (94.7)

2 (5.3)

 

Poorly differentiated

16 (64.0)

9 (36.0)

 

Histology

Keratinizing

36 (90.0)

4 (10.0)

0.177*3

Non-keratinizing

26 (74.3)

9 (25.7)

 

Undifferentiated

1 (100.0)

0 (0.0)

 

Mutational status

Non-mutated

15 (78.9)

4 (21.1)

0.726*2

Mutated

48 (84.2)

9 (15.8)

 

TP53 mutated

Non-mutated

18 (66.7)

9 (33.3)

0.009*2

Mutated

45 (91.8)

4 (8.2)

 

PIK3CA mutated

Non-mutated

57 (85.1)

10 (14.9)

0.178*2

Mutated

6 (66.7)

3 (33.3)

 
  1. TNM classification system stands for tumour, node and metastasis.
  2. HPV status based on p16 + IHC could only be measured in 76 (84.4%) out of the 90 oropharyngeal tumour samples.
  3. SD standard deviation, Unk unknown.
  4. *1Mann-Whitney U test.
  5. *2Fisher’s exact test.
  6. *3Chi-square test.
Back to article page